抗HER2療法により持続的奏効を達成したHER2陽性転移性乳がん患者に対するctDNAの個別化検出（HER2 CR）

基本情報

NCT ID

NCT06663787

ステータス

実施中（募集終了）

試験のフェーズ

-

試験タイプ

観察

目標被験者数

50

治験依頼者名

Nagoya City University

概要

Anti-HER2 therapy, such as trastuzumab and pertuzumab, has significantly improved long-term survival in HER2-positive breast cancer. The updated data of the CLEOPATRA trial showed significant Kaplan-Meier curves, suggesting the potential for a cure. However, the efficacy of maintenance therapy in long-term responders remains unexplored. This study will assess MRD in unresectable HER2-positive breast cancer cases with long-term response using the Signatera™ ctDNA assay, which could contribute to future treatment strategy development.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)